ConductScience.org, home

Paper · 37593607

Brevilin A exerts anti-colorectal cancer effects and potently inhibits STAT3 signaling invitro.

Meng M and 5 others. Heliyon, 2023. Cited by 7 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Brevilin A exerts anti-colorectal cancer effects and potently inhibits STAT3 signaling invitro. Papers, record 37593607. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37593607

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Brevilin A exerts anti-colorectal cancer effects and potently inhibits STAT3 signaling invitro.
PubMed
Journal
Heliyon
PubMed
Year
2023
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
7
iCite
Relative citation ratio, by iCite
0.79
iCite
Revised in PubMed
2023-08-23
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Meng MMingjing
2Tan JJincheng
3Chen HHui
4Shi ZZhiqiang
5Kwan HYHiu-Yee
6Su TTao

Source PubMed

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References52

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
129,289,836Brevilin A induces apoptosis and autophagy of colon adenocarcinoma cell CT26 via mitochondrial pathway and PI3K/AKT/mTOR inactivation.Biomed Pharmacother2018https://conductscience.org/library/papers/29289836PubMed
235,281,907Sesquiterpene Lactones Attenuate Paclitaxel Resistance Via Inhibiting MALAT1/STAT3/ FUT4 Axis and P-Glycoprotein Transporters in Lung Cancer Cells.Front Pharmacol2022https://conductscience.org/library/papers/35281907PubMed
331,282,895HUVEC Tube-formation Assay to Evaluate the Impact of Natural Products on Angiogenesis.J Vis Exp2019https://conductscience.org/library/papers/31282895PubMed
431,500,389Brevilin A, a Sesquiterpene Lactone, Inhibits the Replication of Influenza A Virus In Vitro and In Vivo.Viruses2019https://conductscience.org/library/papers/31500389PubMed
532,328,177Brevilin A induces ROS-dependent apoptosis and suppresses STAT3 activation by direct binding in human lung cancer cells.J Cancer2020https://conductscience.org/library/papers/32328177PubMed
631,690,961Tumor angiogenesis: causes, consequences, challenges and opportunities.Cell Mol Life Sci2020https://conductscience.org/library/papers/31690961PubMed
734,170,703Recent Update on Development of Small-Molecule STAT3 Inhibitors for Cancer Therapy: From Phosphorylation Inhibition to Protein Degradation.J Med Chem2021https://conductscience.org/library/papers/34170703PubMed
832,606,754Brevilin A, a Natural Sesquiterpene Lactone Inhibited the Growth of Triple-Negative Breast Cancer Cells via Akt/mTOR and STAT3 Signaling Pathways.Onco Targets Ther2020https://conductscience.org/library/papers/32606754PubMed
927,832,950The chick embryo chorioallantoic membrane (CAM) assay.Reprod Toxicol2017https://conductscience.org/library/papers/27832950PubMed
1031,371,781Garcinol inhibits esophageal cancer metastasis by suppressing the p300 and TGF-β1 signaling pathways.Acta Pharmacol Sin2020https://conductscience.org/library/papers/31371781PubMed

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.

PMIDTitleJournalYearIn PapersSource
40,835,949Brevilin A, a novel LRRC15 inhibitor, exerts potent anti-rheumatoid arthritis effects by inhibiting the LRRC15/STAT3 signaling pathway.Arthritis Res Ther2025https://conductscience.org/library/papers/40835949PubMed
40,001,571Sesquiterpene Lactones as Promising Phytochemicals to Cease Metastatic Propagation of Cancer.Biomolecules2025https://conductscience.org/library/papers/40001571PubMed
39,350,981Matching traditional Chinese medicine and western medicine-based research: Advanced nutraceutical development for proactive gastric cancer prevention.World J Gastrointest Oncol2024https://conductscience.org/library/papers/39350981PubMed

Genes22

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/37593607

GET https://conductscience.org/api/papers/v1/37593607/references?page=2